Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease

Neurology

Volumn 83, Issue 2, 2014, Pages 142-150

  Dale, Russell C ^a   Brilot, Fabienne ^a   Duffy, Lisa V ^b   Twilt, Marinka ^c   Waldman, Amy T ^d   Narula, Sona ^d   Muscal, Eyal ^e   Deiva, Kumaran ^f   Andersen, Erik ^g   Eyre, Michael R ^h   Eleftheriou, Despina ⁱ   Brogan, Paul A ⁱ   Kneen, Rachel ^j   Alper, Gulay ^k   Anlar, Banu ^l   Wassmer, Evangeline ^m   Heineman, Kirsten ⁿ   Hemingway, Cheryl ^h   Riney, Catherine J ^o   Kornberg, Andrew ^g   Tardieu, Marc ^f   Stocco, Amber ^e   Banwell, Brenda ^d   Gorman, Mark P ^b   Benseler, Susanne M ^c,p,q   Lim, Ming ^r   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f BICÊTRE HOSPITAL   (France)

^g ROYAL CHILDREN'S HOSPITAL   (Australia)

^h GREAT ORMOND STREET HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF LIVERPOOL   (United Kingdom)

^k CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^l HACETTEPE UNIVERSITY   (Turkey)

^m BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

ⁿ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^o MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^p UNIVERSITY OF QUEENSLAND   (Australia)

^q UNIVERSITY OF CALGARY   (Canada)

^r EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ABNORMAL SENSATION; ADOLESCENT; ALLERGIC ENCEPHALOMYELITIS; ANEMIA; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BRADYCARDIA; BRAIN VASCULITIS; BRONCHIECTASIS; CHILD; CHILDHOOD DISEASE; CLOSTRIDIUM DIFFICILE ENTERITIS; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLITIS; CYTOMEGALOVIRUS COLITIS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EMPYEMA; EPILEPTIC STATE; FACE EDEMA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOTENSION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; IMMUNOGLOBULIN M DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MASTOIDITIS; MENTAL DISEASE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM INFLAMMATION; NEUROIMMUNOLOGY; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; NEUTROPENIA; OPSOCLONUS MYOCLONUS SYNDROME; PANCYTOPENIA; PANIC; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANKIN SCALE; RASMUSSEN SYNDROME; RETROSPECTIVE STUDY; SALMONELLOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TOXIC SHOCK SYNDROME; TREATMENT OUTCOME; TREMOR; AGING; AUTOIMMUNE DISEASES; BLOOD CELL COUNT; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIAL; DRUG EFFECTS; INFANT; INFECTION; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; AGING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; BLOOD CELL COUNT; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFECTION; INFLAMMATION; INFUSIONS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84904004074     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000570     Document Type: Article

References (25)

1. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDECC2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90: 2188-2195.
2. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363: 221-232.
3. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54: 2793-2806.
4. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358: 676-688.
5. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006;28: 585-593.
6. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12: 157-165.
7. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65: 1443-1448.
8. Kavcic M, Fisher BT, Seif AE, et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. J Pediatr 2013;162: 1252-1258.
9. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31: 456-473.
10. Highlights of prescribing information. Available at: http://www.gene.com/ download/pdf/rituxan-prescribing.pdf. Accessed February 1, 2014.
11. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. Accessed February 1, 2014.
12. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16: 2825-2833.
13. Bigi S, Fischer U, Wehrli E, et al. Acute ischemic stroke in children versus young adults. Ann Neurol 2011;70: 245-254.
14. Le Sache N, Afanetti M, Deiva K, Chevret L, Tissieres P. Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy. J Neurol 2013;260: 2892-2893.
15. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354: 899-910.
16. Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 2013;81: 710-713.
17. PranzatelliMR, Tate ED, Verhulst SJ, et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonusmyoclonus syndrome. J Pediatr Hematol Oncol 2010;32: e167-e172.
18. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6: 805-815.
19. De La Torre I, LeandroMJ, Valor L, Becerra E, Edwards JC, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology 2012;51: 833-840.
20. Venhoff N, Effelsberg NM, Salzer U, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 2012;7: e37626.
21. Quartier P, Tournilhac O, Archimbaud C, et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 2003;36: e47-e49.
22. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007;110: 2924-2930.
23. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010;68: 369-383.
24. Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009;1: 583-589.
25. Pranzatelli MR, Tate ED, Swan JA, et al. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord 2010;25: 238-242.